AVI BioPharma, Inc. (AVII) Tops Q3 EPS by 3c; Guides FY11 Sales
Tweet Send to a FriendGet Alerts AVII Hot Sheet
Trade AVII Now!
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q3 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06).
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Sees FY2011 revenue of $40-$50 million, versus the consensus of $54.18 million.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- salesforce.com, Inc. (CRM) Reports In-Line Q1 EPS; Issues In-Line Q2, FY14 Outlook
- Marvell Technology Group (MRVL) Tops Q1 EPS by 5c; Issues Solid Outlook
- GameStop Corp. (GME) Tops Q1 EPS by 6c; Boosts Lower-End of FY13 EPS Outlook
Create E-mail Alert Related Categories
Earnings, Guidance
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
